ProQR Therapeutics
PRQR
47 hedge funds and large institutions have $37M invested in ProQR Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 5 closing their positions.
255% more call options, than puts
Call options by funds: $156K | Put options by funds: $44K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
52% more capital invested
Capital invested by funds: $24.3M → $37M (+$12.6M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 46 → 47 (+1)
0.4% less ownership
Funds ownership: 23.16% → 22.76% (-0.4%)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$592K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$120K |
| 3 |
VF
Virtu Financial
New York
|
+$53.6K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$46.1K |
| 5 |
Millennium Management
New York
|
+$44.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$352K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$246K |
| 3 |
JP Morgan Chase
New York
|
-$224K |
| 4 |
Two Sigma Investments
New York
|
-$125K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$96K |
PRQR Hedge Fund Activity: Q4 2023 in Review
47 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2023, worth a combined $37M — up 52% from $24.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PRQR positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 12 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $592K. The largest seller was Morgan Stanley, cutting an estimated $352K.
- 47 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2023, up from 46 in Q3 2023.
- Funds reported $37M of ProQR Therapeutics stock for Q4 2023, up 52% quarter-over-quarter.
- 6 funds opened new ProQR Therapeutics positions in Q4 2023 and 5 closed out, a net change of +1 holder.
- The largest ProQR Therapeutics buyer in Q4 2023 was Deutsche Bank, an estimated $592K added.
- The largest ProQR Therapeutics seller in Q4 2023 was Morgan Stanley, an estimated $352K sold.
Based on aggregated 13F filings for Q4 2023.